 Pfizer Inc. said Thursday that a Phase 3 study of fidanacogene elaparvovec for the treatment of hemophilia B in adult males met its primary endpoint of superiority in the annualized bleeding rate ABR. The drug maker PFE, -0.65 said key secondary endpoints demonstrated a 78 reduction in treated ABR and a 92 reduction in annualized infusion rate. 